The P-II/III (SKYSCRAPER-06) study assesses tiragolumab + Tecentriq & CT vs Keytruda & CT as a 1L treatment of locally advanced, inoperable or metastatic non-squamous NSCLC patients (n=542)
The study did not reach its 1EPs of PFS & OS (immature), depicting a reduced efficacy among the ITT population due to which the patients & investigators will be unblinded and the trial will be terminated. Data will be highlighted at future conferences and shared with health authorities
The company will make necessary changes in the tiragolumab program based on these outcomes. Further P-III studies, evaluating different treatment options & indications from SKYSCRAPER-06, are underway
Ref: Roche | Image: Roche
Related News:- Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
